経口固形製剤で、小児や老人、嚥下困難な患者に最適。
Parvulet is an oral solid dosage form that, with the application of water, achieves a texture similar to applesauce
- 30秒で簡単に投与可能
- 製剤に配合された嚥下補助剤
- 窒息の危険性がなく、自然な嚥下メカニズムを模倣
- 分散性顆粒および錠剤で入手可能
パービュレットは複数の課題に対応
- 嚥下障害のある患者に最適
- 呼吸困難患者
- 粘膜炎患者
- 小児および老年人口
- 高い薬剤負荷が可能
- 毎回の正確な投与
- 患者のアドヒアランス向上
- 飲みやすいテクスチャー
- 味と匂いのマスキング
パービュレットは患者に優しいフォーマット
研究によると、老年人口の60～79％、小児人口の25～45％が嚥下障害を経験するという。
最終的な食感がアップルソースに似ている経口固形剤：
- 30秒で簡単に投与可能
- 製剤に配合された嚥下補助剤
- 窒息の危険性がなく、自然な嚥下メカニズムを模倣
- 分散性顆粒および錠剤で入手可能
専門家と話す
スリニヴァサン・シャンムガム博士
Executive Director, Pharmaceutical Sciences, Business Support, and New Technologies
Dr. Srinivasan Shanmugam is involved in the development and expansion of Adare’s pharmaceutical technology portfolio and supports product development, co-development, and tech transfer opportunities. Dr. Shanmugam has a Ph.D. M.S., and a B.S. in Pharmacy. Dr. Shanmugam has more than 20 years of experience in designing and development of conventional, NDDS/alternate, advanced/modified drug delivery systems, and pharmaceutical platform technologies for oral and other routes of administration. His expertise includes enabling technologies for challenging drugs and developing platform technologies. Additionally, his expertise includes patient-centric solutions focusing on pediatric and geriatric populations to achieve dose convenience, flexibility, and precision. Dr. Shanmugam has published numerous research articles, holds multiple patents, and is a reviewer/editorial member of various prestigious journals. Shanmugam’s recent work focuses on product development solutions for special patient populations like pediatric and geriatric populations.
